Cytokinetics shares climb as investors refocus on MYQORZO launch momentum and expansion runway

Cytokinetics (CYTK) is up 6.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The day’s gain appears tied to a renewed bullish read-through on the company’s transition into a commercial-stage story for MYQORZO (aficamten), alongside continued investor emphasis on label-expansion potential after recent Phase 3 results. With no single, clearly identifiable breaking headline, the move looks more like positioning around commercialization progress and the broader market opportunity implied by recent clinical updates.

Details:

The company recently reported positive topline Phase 3 results for aficamten in non-obstructive hypertrophic cardiomyopathy, which could expand the addressable market beyond the initial obstructive indication.

MYQORZO has entered active commercialization, with the company highlighting ongoing scientific and clinical evidence-generation meant to support physician adoption and payer access over time.

The company began its first commercial European launch in Germany following earlier European authorization, adding a new geography to the rollout narrative.

This could also be amplified by investors revisiting prior expectations for stronger long-term sales potential following late-stage data updates.

Sources:

Cytokinetics Investor Relations, GlobeNewswire, S&P Global Market Intelligence

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CYTK Insider Trading Activity

$CYTK insiders have traded $CYTK stock on the open market 44 times in the past 6 months. Of those trades, 0 have been purchases and 44 have been sales.

Here’s a breakdown of recent trading of $CYTK stock by insiders over the last 6 months:

ANDREW CALLOS (EVP, Chief Commercial Officer) has made 0 purchases and 18 sales selling 126,633 shares for an estimated $8,232,891.
ROBERT I BLUM (President & CEO) has made 0 purchases and 9 sales selling 89,532 shares for an estimated $5,885,472.
FADY IBRAHAM MALIK (EVP Research & Development) has made 0 purchases and 10 sales selling 35,640 shares for an estimated $2,355,631.
SUNG LEE (EVP, Chief Financial Officer) has made 0 purchases and 2 sales selling 28,841 shares for an estimated $2,144,364.
WENDELL WIERENGA has made 0 purchases and 2 sales selling 24,032 shares for an estimated $1,625,200.
JOHN T HENDERSON sold 20,000 shares for an estimated $1,519,400
B LYNNE PARSHALL sold 5,000 shares for an estimated $370,400
EDWARD M. MD KAYE sold 2,933 shares for an estimated $223,171

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$CYTK Hedge Fund Activity

We have seen 250 institutional investors add shares of $CYTK stock to their portfolio, and 225 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 9,690,092 shares (-50.8%) from their portfolio in Q4 2025, for an estimated $615,708,445
AVORO CAPITAL ADVISORS LLC added 3,333,333 shares (+inf%) to their portfolio in Q1 2026, for an estimated $217,399,978
FMR LLC removed 2,084,612 shares (-16.3%) from their portfolio in Q1 2026, for an estimated $135,958,394
DEEP TRACK CAPITAL, LP removed 1,962,678 shares (-58.8%) from their portfolio in Q1 2026, for an estimated $128,005,859
PARADIGM BIOCAPITAL ADVISORS LP added 1,480,857 shares (+inf%) to their portfolio in Q1 2026, for an estimated $96,581,493
BALYASNY ASSET MANAGEMENT L.P. added 992,545 shares (+inf%) to their portfolio in Q1 2026, for an estimated $64,733,784
UBS GROUP AG added 945,821 shares (+83.6%) to their portfolio in Q1 2026, for an estimated $61,686,445

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$CYTK Analyst Ratings

Wall Street analysts have issued reports on $CYTK in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Barclays issued a "Overweight" rating on 01/28/2026
Needham issued a "Buy" rating on 12/22/2025
HC Wainwright & Co. issued a "Buy" rating on 12/22/2025
Citizens issued a "Market Outperform" rating on 12/22/2025
Goldman Sachs issued a "Buy" rating on 12/19/2025

To track analyst ratings and price targets for $CYTK, check out Quiver Quantitative's $CYTK forecast page.

$CYTK Price Targets

Multiple analysts have issued price targets for $CYTK recently. We have seen 16 analysts offer price targets for $CYTK in the last 6 months, with a median target of $99.5.

Here are some recent targets:

Eric Joseph from Citigroup set a target price of $99.0 on 05/19/2026
Tessa Romero from JP Morgan set a target price of $97.0 on 05/12/2026
Joseph Pantginis from HC Wainwright & Co. set a target price of $140.0 on 05/11/2026
Yanan Zhu from Wells Fargo set a target price of $105.0 on 05/07/2026
Leonid Timashev from RBC Capital set a target price of $119.0 on 05/06/2026
Jeffrey Hung from Morgan Stanley set a target price of $103.0 on 05/06/2026
James Condulis from Stifel set a target price of $108.0 on 05/06/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.